MEDIA ADVISORY --- BIO CEO & Investor Conference 2002: Highlights for Wednesday, February 20, 2002

8:00 - 9:20 a.m.
Opening Plenary
Grand Ballroom
2001: A Record Year in Biotech M & A - This panel will feature executives from Vertex Pharmaceuticals, Aviron, Aurora Biosciences Corporation, Millennium Pharmaceuticals, Inc., and MedImmune.

10:50 a.m. - 12: 00 p.m.
Investor Session 1
Jade Room
New Therapeutics: Caring for the Heart - Panel speakers will discuss the challenges and opportunities currently affecting companies in the cardiovascular therapeutics space.

10:50 a.m. - 12:00 p.m.
Investor Session 2
Astor Room
Autoimmune Disease: Inflammation From Anthrax to Arthritis - Led by Franklin Berger of JP Morgan H&Q, this panel will discuss the important role of understanding inflammation and how it will impact the treatment of patients with a range of conditions.

12:10 - 1:40 p.m.
Grand Ballroom
Keynote speaker, Harold Varmus, Memorial Sloan-Kettering, will discuss “Changes in Academic Science and Effects on Biotech.”

1:50 - 3:10 p.m.
Investor Session 3
Jade Room
IP In the Age of Genomics: Will Festo Change the Game? - Learn how the U.S. Supreme Court case of Festo vs. Shoketsu Kinzoku Kgoyo Kabushiki will substantially impact the application and enforcement process. Hear how this decision can affect your investment portfolio.

2:20 - 3:40 p.m.
CEO Roundtable 3
East Foyer
Cloning Stem Cells: Public Policy and the Promise of Regenerative Medicine - This panel will discuss the scientific potential of regenerative medicine and various policy issues surrounding this field, including the impact of pending legislation.

1:50 - 3:10 p.m.
CEO Roundtable 4
West Foyer
Current Trends In Equity Financing - This panel will provide an overview of the most common methods biotechnology companies use to raise new equity capital.

4:30 - 5:50 p.m.
Investor Session 5
Jade Room
The 4 R’s of Stem Cell Therapeutics: Repair, Regenerate, Rejuvenate, Replace - William J. Kridel Jr., an experienced transaction advisor in this field, will describe stem cell biology and the inter-relationships of the various stem cell lineages. Individual panelists will describe their companies and activities.

4:30 - 5:50 p.m.
CEO Roundtable 6
West Foyer
Recent Developments and the Interface of Patent and FDA Regulations: Strategies to Consider When Seeking FDA Approval - The panel will discuss the importance of understanding how key patent and FDA regulations for new drug filings are inter-related.

BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products. For more information, please visit